AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20133929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg for 7 days
Number of subjects: 213
Study 20133929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 1 month
Number of subjects: 1367
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 6 months
Number of subjects: 1367
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 12 months
Number of subjects: 1367
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 2 years
Number of subjects: 1367
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 4 years
Number of subjects: 1367
Study 17394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical preventive drug treatment with heart attack postponement of 8 years
Number of subjects: 1367
Study 16344321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sx + Ax (surgery plus axillary clearance) followed by tamoxifen for 5 years
Number of subjects: 473
Study 16344321 — intervention group
Group type: COMPARATOR
Intervention: Sx (surgery without axillary clearance) followed by tamoxifen for 5 years
Number of subjects: 473
Study 12815686 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) pulses applied with optimized modulation of flip angle according to phase-encoded view's distance to the center of k-space.
Number of subjects: 11
Study 10469936 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin injections into the gastrocnemius muscle
Number of subjects: 20
Study 10469936 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle injections into the gastrocnemius muscle
Number of subjects: 20
Study 8596827 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 107
Study 1942019 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for skin cancer detection and prevention
Number of subjects: 0
Study 6133072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine added to urine drainage bags
Number of subjects: 0
Study 6133072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 0
Study 30679414 — intervention group
Group type: EXPERIMENTAL
Intervention: ALEM plus tacrolimus (TAC) monotherapy (Group A)
Number of subjects: 30
Study 30679414 — intervention group
Group type: COMPARATOR
Intervention: ATG induction plus TAC, mycophenolate mofetil (MMF) and steroids (Group B)
Number of subjects: 30
Study 26237777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 28
Study 26237777 — intervention group
Group type: COMPARATOR
Intervention: Wake group
Number of subjects: 28
Study 24811758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigue la Huella intervention
Number of subjects: 682
Study 24811758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 682
Study 21289590 — intervention group
Group type: COMPARATOR
Intervention: Private physiotherapy (private PT)
Number of subjects: 160
Study 21289590 — intervention group
Group type: COMPARATOR
Intervention: Public physiotherapy (public PT)
Number of subjects: 160
Study 19605408 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath laryngoscope
Number of subjects: 120
Study 19605408 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study 19605408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laryngoscopes
Number of subjects: 120
Study 17445098 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) at doses of 110 to 260 U per treatment cycle
Number of subjects: 369
Study 17445098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 17445098 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA
Number of subjects: 369
Study 15199622 — intervention group
Group type: EXPERIMENTAL
Intervention: Taizhi'an Capsule (TZA)
Number of subjects: 78
Study 15199622 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (PVT)
Number of subjects: 78
Study 11429346 — intervention group
Group type: EXPERIMENTAL
Intervention: CaCl(2) 20 mg/kg and protamine 5 mg/kg mixed and infused over 10 min
Number of subjects: 147
Study 11429346 — intervention group
Group type: COMPARATOR
Intervention: CaCl(2) 10 mg/kg as a bolus followed by a 10‐min infusion of protamine 5 mg/kg and CaCl(2) 10 mg/kg
Number of subjects: 147
Study 9153741 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of urine specimens for Chlamydia trachomatis testing
Number of subjects: 0
Study 9153741 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral surveys combined with STD testing
Number of subjects: 0
Study 8181345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 micrograms every 6 hours)
Number of subjects: 42
Study 8181345 — intervention group
Group type: COMPARATOR
Intervention: 0.9 percent saline solution (placebo)
Number of subjects: 42
Study 3948547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) albuterol (250 micrograms)
Number of subjects: 0
Study 3948547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) or subcutaneous albuterol (500 micrograms)
Number of subjects: 0
Study 3948547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from all three albuterol routes
Number of subjects: 0
Study 3948547 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (0.3 ml, 1:1,000)
Number of subjects: 0
Study 3948547 — intervention group
Group type: EXPERIMENTAL
Intervention: IV albuterol (250 micrograms), IM albuterol (500 micrograms), or subcutaneous albuterol (500 micrograms)
Number of subjects: 0
Study 31037360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of VCAM‐1 in patients with severe OA of the hips
Number of subjects: 100
Study 31037360 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (age and sex-matched)
Number of subjects: 100
Study 30048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot Intervention (PI)
Number of subjects: 307
Study 30048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 307
Study 30048234 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Enhanced Intervention (EI) to Pilot Intervention (PI)
Number of subjects: 307
Study 27816738 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine labour epidural analgesia (EA)
Number of subjects: 488
Study 27816738 — intervention group
Group type: COMPARATOR
Intervention: Analgesia on request
Number of subjects: 488
Study 24885542 — intervention group
Group type: EXPERIMENTAL
Intervention: Full coverage eligibility for 26 weeks
Number of subjects: 1380
Study 24885542 — intervention group
Group type: COMPARATOR
Intervention: No coverage
Number of subjects: 1380
Study 23763767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir/P/R
Number of subjects: 0
Study 20202719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell telephone CPR instructions
Number of subjects: 0
Study 19203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated zidovudine/lamivudine/abacavir plus tenofovir
Number of subjects: 23
Study 19203904 — intervention group
Group type: COMPARATOR
Intervention: Genotype-guided salvage regimen (Control)
Number of subjects: 23
Study 17011959 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision (1.5 mm)
Number of subjects: 70
Study 17011959 — intervention group
Group type: COMPARATOR
Intervention: Coaxial small-incision (2.75 mm)
Number of subjects: 70
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0/Definit
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond1/FiltekP60
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1/SureFil
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite/Tetric Condensable
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerr Bonding/Prodigy Condensable
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure/Virtuoso
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite/Tetric flow/Tetric Ceram
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma/Solitaire
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac/Cavex Packable
Number of subjects: 100
Study 14621243 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐step/Pyramid
Number of subjects: 100
Study 10889104 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 58
Study 10889104 — intervention group
Group type: COMPARATOR
Intervention: RNFL photography
Number of subjects: 58
Study 8884508 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance monitoring
Number of subjects: 132
Study 8884508 — intervention group
Group type: COMPARATOR
Intervention: Temperature monitoring
Number of subjects: 132
Study 1410155 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a cigarette prior to the continuous performance task (CPT)
Number of subjects: 0
Study 1410155 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking session
Number of subjects: 0
Study 1410155 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking session
Number of subjects: 0
Study 1410155 — intervention group
Group type: COMPARATOR
Intervention: No smoking session
Number of subjects: 0
Study 1410155 — intervention group
Group type: EXPERIMENTAL
Intervention: Light inhalers (pre-smoked to post-task increase in expired air carbon monoxide)
Number of subjects: 0
Study 7020176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antithymocyte globulin (ATG) given in higher doses before signs of engraftment were evident.
Number of subjects: 0
Study 7020176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned but implied as standard care without ATG).
Number of subjects: 0
Study 31869853 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg along with conventional treatment
Number of subjects: 40
Study 31869853 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 40
Study 30307614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen intervention (SPF 15 applied at ≥ 2 mg cm−2)
Number of subjects: 62
Study 30307614 — intervention group
Group type: COMPARATOR
Intervention: Typical sunscreen use (own sunscreens applied at < 2 mg cm−2)
Number of subjects: 62
Study 30307614 — intervention group
Group type: COMPARATOR
Intervention: Laboratory study (3 SED from three different spectra)
Number of subjects: 62
Study 29220421 — intervention group
Group type: COMPARATOR
Intervention: D110
Number of subjects: 1834
Study 29220421 — intervention group
Group type: COMPARATOR
Intervention: co-D110
Number of subjects: 1834
Study 29220421 — intervention group
Group type: COMPARATOR
Intervention: di-D110
Number of subjects: 1834
Study 29220421 — intervention group
Group type: COMPARATOR
Intervention: D150
Number of subjects: 1834
Study 26110694 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 4-6 × 30 s of all-out cycling efforts at approximately 180% of peak workload with 4-min recovery
Number of subjects: 26
Study 26110694 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MIT) - 40- to 60-min continuous cycling at 60% of peak workload
Number of subjects: 26
Study 26110694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIT and MIT
Number of subjects: 26
Study 25713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 67
Study 25713888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21134477 — intervention group
Group type: EXPERIMENTAL
Intervention: High weight loss (>5%)
Number of subjects: 76
Study 21134477 — intervention group
Group type: COMPARATOR
Intervention: Low weight loss (<5%)
Number of subjects: 76
Study 21134477 — intervention group
Group type: COMPARATOR
Intervention: No weight loss (0% or gain)
Number of subjects: 76
Study 19826197 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational method for incorporating patient motion into tomotherapy dose calculations
Number of subjects: 0
Study 17500624 — intervention group
Group type: EXPERIMENTAL
Intervention: BWLP+SC (MI)
Number of subjects: 55
Study 17500624 — intervention group
Group type: COMPARATOR
Intervention: BWLP (SC matched)
Number of subjects: 55
Study 17160199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (L) and zeaxanthin (Z) supplementation
Number of subjects: 0
Study 17160199 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12560305 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 75 mg
Number of subjects: 90
Study 12560305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 75 mg plus droperidol 2.5 mg
Number of subjects: 90
Study 12560305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 75 mg plus clonidine 150 microg
Number of subjects: 90
Study 10581660 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms b.i.d. for 6 months
Number of subjects: 40
Study 10581660 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 8652903 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA in mixture form
Number of subjects: 45
Study 8652903 — intervention group
Group type: COMPARATOR
Intervention: CsA in capsule form
Number of subjects: 45
Study 2011617 — intervention group
Group type: COMPARATOR
Intervention: 0 g L-Tryptophan
Number of subjects: 14
Study 2011617 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g L-Tryptophan
Number of subjects: 14
Study 2011617 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g L-Tryptophan
Number of subjects: 14
Study 2011617 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g L-Tryptophan
Number of subjects: 14
Study 6753949 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-induced relaxation training
Number of subjects: 32
Study 6753949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 29076125 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intracranial vasculopathy defined by magnetic resonance angiography (MRA)
Number of subjects: 110
Study 29076125 — intervention group
Group type: COMPARATOR
Intervention: Normal transcranial Doppler (TCD) velocities
Number of subjects: 110
Study 28502609 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 482
Study 28502609 — intervention group
Group type: COMPARATOR
Intervention: infliximab originator
Number of subjects: 482
Study 25559299 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) with 10 mL of 1% lidocaine
Number of subjects: 80
Study 25559299 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study 23966238 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 37
Study 21426755 — intervention group
Group type: EXPERIMENTAL
Intervention: No-reflow group
Number of subjects: 119
Study 21426755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflow group
Number of subjects: 119
Study 21426755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 18768009 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate assistance in accessing housing and assistance in paying first and last month's rent
Number of subjects: 14
Study 18768009 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 16169312 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 100 IU/kg subcutaneously twice daily (n = 220)
Number of subjects: 438
Study 16169312 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin, 175 IU/kg subcutaneously once daily (n = 218)
Number of subjects: 438
Study 14616170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 19
Study 14616170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 19
Study 14616170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14616170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d. and Tegaserod 6 mg b.d.
Number of subjects: 19
Study 10475720 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (40mg)
Number of subjects: 81
Study 10475720 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 81
Study 10829992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis patients
Number of subjects: 50
Study 1815963 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 19
Study 1815963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6125202 — intervention group
Group type: EXPERIMENTAL
Intervention: RX 781094 at a dose of 0.1 mg/kg i.v.
Number of subjects: 6
Study 6125202 — intervention group
Group type: EXPERIMENTAL
Intervention: RX 781094 at a dose of 0.05 mg/kg i.v.
Number of subjects: 6
Study 6125202 — intervention group
Group type: COMPARATOR
Intervention: Clonidine at a dose of 0.1 mg and 0.2 mg i.v.
Number of subjects: 6
Study 31990414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0
Study 31990414 — intervention group
Group type: COMPARATOR
Intervention: Vismodegib
Number of subjects: 0
Study 31043453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience intervention
Number of subjects: 264
Study 31043453 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 264
Study 27891657 — intervention group
Group type: EXPERIMENTAL
Intervention: High obesity risk group (based on parental weight)
Number of subjects: 167
Study 27891657 — intervention group
Group type: COMPARATOR
Intervention: Low obesity risk group (based on parental weight)
Number of subjects: 167
Study 27891657 — intervention group
Group type: EXPERIMENTAL
Intervention: High obesity risk group
Number of subjects: 167
Study 25528523 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose vaccination
Number of subjects: 100
Study 25528523 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose vaccination
Number of subjects: 100
Study 25528523 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses in lifetime
Number of subjects: 100
Study 23807273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 10 mg
Number of subjects: 208
Study 23807273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 25 mg
Number of subjects: 208
Study 23807273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 208
Study 23807273 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (control) 600 mg
Number of subjects: 208
Study 23807273 — intervention group
Group type: EXPERIMENTAL
Intervention: All DTG treatment groups combined
Number of subjects: 208
Study 23807273 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 208
Study 23807273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 208
Study 21061408 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized intervention material
Number of subjects: 628
Study 21061408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 628
Study 21061408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity improvements
Number of subjects: 628
Study 18669546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise referral scheme
Number of subjects: 0
Study 18669546 — intervention group
Group type: COMPARATOR
Intervention: Advice booklet
Number of subjects: 0
Study 17520463 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (2 x 50 mg/week)
Number of subjects: 62
Study 17520463 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (2 x 25 mg/week)
Number of subjects: 62
Study 17520463 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 62
Study 17520463 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 62
Study 14966943 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone intervention
Number of subjects: 85
Study 14966943 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 85
Study 11409486 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF (filgrastim)
Number of subjects: 80
Study 11409486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9229279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour interactive seminar and received an informational pamphlet and advance directive forms
Number of subjects: 187
Study 9229279 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet and forms only (Control)
Number of subjects: 187
Study 8134674 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (4‐6.5 mg/kg)
Number of subjects: 14
Study 8134674 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5‐2.5 mg/kg)
Number of subjects: 14
Study 8134674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both induction agents
Number of subjects: 14
Study 3123756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C plus carmofur (HCFU)
Number of subjects: 170
Study 3123756 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C only
Number of subjects: 170
Study 29355939 — intervention group
Group type: COMPARATOR
Intervention: Energy-adjusted Dietary Inflammatory Index (E-DII) scores, highest quintile (Q5) vs lowest quintile (Q1)
Number of subjects: 101449
Study 29355939 — intervention group
Group type: COMPARATOR
Intervention: E-DII scores during follow up <4 years
Number of subjects: 101449
Study 29355939 — intervention group
Group type: COMPARATOR
Intervention: E-DII scores during follow up ≥4 years
Number of subjects: 101449
Study 29355939 — intervention group
Group type: COMPARATOR
Intervention: E-DII from food only
Number of subjects: 101449